Dysregulation of alternative splicing in spinocerebellar ataxia type 1
Human Molecular Genetics · 07.01.2024 · 33 (2) · 138-149
DOI: 10.1093/hmg/ddad170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 06.10.2023. Verfasst von Victor Olmos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Yale School of Medicine, 295 Congress Avenue, New Haven, CT 06510, United States. Hauptthemen laut MEDLINE: Alternative Splicing, Spinocerebellar Ataxias. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NICHD NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Spinocerebellar ataxia type 1 is caused by an expansion of the polyglutamine tract in ATAXIN-1. Ataxin-1 is broadly expressed throughout the brain and is involved in regulating gene expression. However, it is not yet known if mutant ataxin-1 can impact the regulation of alternative splicing events. We performed RNA sequencing in mouse models of spinocerebellar ataxia type 1 and identified that mutant ataxin-1 expression abnormally leads to diverse splicing events in the mouse cerebellum of spinocerebellar ataxia type 1. We found that the diverse splicing events occurred in a predominantly cell autonomous manner. A majority of the transcripts with misregulated alternative splicing events were previously unknown, thus allowing us to identify overall new biological pathways that are distinctive to those affected by differential gene expression in spinocerebellar ataxia type 1. We also provide evidence that the splicing factor Rbfox1 mediates the effect of mutant ataxin-1 on misregulated alternative splicing and that genetic manipulation of Rbfox1 expression modifies neurodegenerative phenotypes in a Drosophila model of spinocerebellar ataxia type 1 in vivo. Together, this study provides novel molecular mechanistic insight into the pathogenesis of spinocerebellar ataxia type 1 and identifies potential therapeutic strategies for spinocerebellar ataxia type 1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Yale School of Medicine, 295 Congress Avenue, New Haven, CT 06510, United States.
- Department of Cell Biology, Yale School of Medicine, 10 Amistad Street, New Haven, CT 06510, United States.
- Yale Stem Cell Center, Yale School of Medicine, 10 Amistad Street, New Haven, CT 06510, United States.
- Interdepartmental Neuroscience Program, Yale School of Medicine, 295 Congress Avenue, New Haven, CT 06510, United States.
- Department of Neuroscience, Yale School of Medicine, 295 Congress Avenue, New Haven, CT 06510, USA.
- Yale College, 433 Temple Street, New Haven, CT 06510, United States.
Förderung
- NINDS NIH HHS
- NICHD NIH HHS
- NIA NIH HHS
- NIH
Zitieren
APA
Olmos, V., Thompson, E. N., Gogia, N., Luttik, K., Veeranki, V., Ni, L., Sim, S., Chen, K., Krause, D. S., & Lim, J. (2024). Dysregulation of alternative splicing in spinocerebellar ataxia type 1. Human Molecular Genetics, 33(2), 138-149. https://doi.org/10.1093/hmg/ddad170
Vancouver
Olmos V, Thompson EN, Gogia N, Luttik K, Veeranki V, Ni L, et al. Dysregulation of alternative splicing in spinocerebellar ataxia type 1. Human Molecular Genetics. 2024;33(2):138-149. doi:10.1093/hmg/ddad170
BibTeX
@article{Olmos2024,
author = {Olmos, Victor and Thompson, Evrett N and Gogia, Neha and Luttik, Kimberly and Veeranki, Vaishnavi and Ni, Luhan and Sim, Serena and Chen, Kelly and Krause, Diane S and Lim, Janghoo},
title = {Dysregulation of alternative splicing in spinocerebellar ataxia type 1},
journal = {Human Molecular Genetics},
year = {2024},
volume = {33},
number = {2},
pages = {138--149},
doi = {10.1093/hmg/ddad170}
}
EUVIMED